DxTerity to Present at 12th Annual Canaccord Genuity Medical Technology & Diagnostics Forum
DxTerity will present on Thursday, November 15, 2018 at 11:30 a.m. PT (2:30 p.m. ET) in New York
LOS ANGELES, Nov. 6, 2018 /PRNewswire/ -- DxTerity, a molecular information and diagnostics company developing at-home RNA monitoring blood tests for immune-mediated diseases, today announced that Founder and CEO Bob Terbrueggen, Ph.D. and SVP of Business Development and CFO James Healy are scheduled to present at the 12th Annual Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 15, 2018 at the Westin Grand Central in New York, NY at 11:30 a.m. PT (2:30 p.m. ET).
In its twelfth year, the Medical Technologies and Diagnostics Forum is a one-day event that profiles public and private Med-Tech and Diagnostic companies, including those in Diagnostics, Personalized Medicine, and Next Generation Sequencing. Participating company presentations are hosted throughout the day, highlighting some of the most important topics in the Med-Tech space.
DxTerity recently presented key findings from two direct-to-patient clinical studies at the 2018 ACR/ARHP Annual Meeting, including the introduction of its Autoimmune Profile Test (AIP). The AIP test is being developed to be capable of providing high precision gene expression analysis of 12 immune-related disease pathways including type 1 interferon (IFN) levels in a simple at-home blood test. DxTerity has also begun early recruitment into its AIP Registry, the academic-industry consortium it is building to help accelerate autoimmune disease research. For more information on the Registry, email firstname.lastname@example.org.
DxTerity is a molecular information and diagnostics company bringing precision medicine to autoimmune with from-home RNA monitoring. DxTerity also provides services and technologies to partner organizations, including population-scale genomic studies. For more information, please visit DxTerity.com or follow us on LinkedIn, Twitter, Facebook.